A taron ASCO na 2018, sakamakon binciken da aka yi akan chemotherapy ya jawo hankali sosai. Nazarin ya nuna cewa sabon ilimin chemotherapy zai iya magance cutar kansar pancreatic da ake kira "sarkin ciwon daji". Don wannan ciwon daji tare da tsinkaya mara kyau, wannan chemotherapy na iya tsawaita rayuwar majiyyaci har zuwa watanni 20!
A cikin gwaji na asibiti da ake kira PRODIGE 24 / CCTG PA.6, masu binciken sun tattara adadi mai yawa na marasa lafiya tare da maras cutar sanyin hanji adenocarcinoma (PDAC), wanda kuma shine mafi yawan sankarar cutar sankara, ana daukar kashi 90% na dukkan shari'oin. %. Wadannan marasa lafiya sun yi aikin tiyata don cire kumburin. A cikin makonni 3-12 bayan aikin tiyata, duka marasa lafiya 493 sun kasu kashi biyu, rukuni guda ya karɓi maganin gemcitabine (gemcitabine), ɗayan rukunin kuma sun sami sabon maganin mFOLFIRINOX (wanda aka gyara FOLFIRINOX). Latterarshen ya ƙunshi abubuwa huɗu daban-daban na chemotherapy, ciki har da oxaliplatin, leucovorin, irinotecan, da 5-fluorouracil.
Binciken ya nuna cewa tare da bin hanyar 33.6 na watanni, rashin lafiyar cutar marasa lafiya na marasa lafiya a cikin kungiyar mFOLFIRINOX ya kasance mafi girma fiye da na ƙungiyar gemcitabine (watanni 21.6 - watanni 12.8). Dangane da rayuwa gabaɗaya, na farkon ya ma fi na watanni 20 da suka gabata (watanni 54.4 - 35.0). Tare da ƙarin fa'idodi na rayuwa, ana iya sarrafa abubuwan illa na chemotherapy.
Dangane da shirin, masu binciken za su ci gaba da binciken mafi kyawun lokacin don maganin don fahimtar ko marasa lafiya za su iya karbar magani kafin a yi musu aiki don rage ƙwayar cutar, don haka rage haɗarin ƙwayar micrometastasis da ƙara yiwuwar yiwuwar cutar ta cire gaba daya ta tiyata Muna fatan sauraron ƙarin labarai masu kyau game da wannan maganin kuma bari marasa lafiya da ke fama da cutar sankarau su ga bege.
